| Literature DB >> 34744447 |
Ci Dian Dan Zeng1, Yi Xin Tong1, Ai Tang Xiao1, Chun Gao1, Sheng Zhang1.
Abstract
BACKGROUND: Immune function influenced patients' recovery from major abdominal surgery. The aim of this study is to explore the clinical feasibility of peripheral lymphocyte absolute counts for predicting short-term surgical outcomes in gastric cancer patients after laparoscopic D2 gastrectomy.Entities:
Keywords: absolute counts of peripheral lymphocyte subsets; gastric cancer; immune function; inflammatory cytokines; surgical outcome
Year: 2021 PMID: 34744447 PMCID: PMC8565983 DOI: 10.2147/JIR.S335847
Source DB: PubMed Journal: J Inflamm Res ISSN: 1178-7031
The Demographic and Laboratory Characteristics of All Patients (n=137)
| Variables | All Patients (n=137) |
|---|---|
| Age, mean (SD), years | 58.0±11.5 |
| Gender | |
| Male | 86 (62.8%) |
| Female | 51 (37.2%) |
| Body mass index mean (SD), kg/m2 | 22.8±3.4 |
| Smoking | |
| No | 108 (78.8%) |
| Yes | 29 (21.2%) |
| Alcohol | |
| No | 112 (81.8%) |
| Yes | 25 (18.2%) |
| Hypertension | |
| No | 109 (79.6%) |
| Yes | 28 (20.4%) |
| Diabetes | |
| No | 132 (96.4%) |
| Yes | 5 (3.6%) |
| Albumin (g/L), mean (SD) | 39.8±4.4 |
| Prealbumin (mg/L), mean (SD) | 211.1±63.8 |
| Absolute lymphocyte count (×109/L), mean (SD) | 1.6±0.6 |
| Hemoglobin (g/L), mean (SD) | 116.9±25.6 |
| Preoperative serum CEA | |
| Normal (<5 ng/mL) | 103 (75.2%) |
| Elevated (≥5 ng/mL) | 34 (24.8%) |
| Lymph node metastasis | |
| No | 82 (59.9%) |
| Yes | 55 (40.1%) |
| TNM stage | |
| I | 23 (16.8%) |
| II | 41 (29.9%) |
| III | 63 (46.0%) |
| IV | 10 (7.3%) |
| Lauren classification | |
| Intestinal | 69 (50.4%) |
| Diffuse | 45 (32.8%) |
| Mixed | 23 (16.8%) |
| Tumor location | |
| Upper | 25 (18.2%) |
| Middle | 33 (24.1%) |
| Lower | 79 (57.7%) |
| Operation type | |
| Distal gastrectomy | 102 (74.5%) |
| Total gastrectomy | 25 (18.2%) |
| Distal gastrectomy and liver resection | 10 (7.3%) |
| First flatus, h, (IQR) | 60 (48, 72) |
| First defecation, h, (IQR) | 72 (48, 84) |
| Postoperative duration of hospital stay, median, days | 9 (8, 11) |
| Postoperative complications | |
| No | 116 (84.7%) |
| Grade 1 and 2 | 20 (14.6%) |
| Grade 3 | 1 (0.7%) |
| Adjuvant chemotherapy | |
| No | 46 (33.6%) |
| Yes | 91 (66.4%) |
Abbreviations: SD, standard deviation; CEA, carcinoembryonic antigen. IQR, interquartile range.
Figure 1Correlation between absolute counts of peripheral lymphocyte subsets and gender (A), age (B), serum albumin level (C) and serum prealbumin level (D). *Represents significant differences.
Figure 2The comparison of T cell absolute count (A), B cell absolute count (B), CD4+ T cell count (C) and CD8+ T cell absolute count (D) in patients with different clinical stages. *Represents significant differences.
Figure 3Perioperative dynamic change of T cell absolute count (A), B cell absolute count (B) and NK cell count (C) in gastric cancer patients.
Figure 4Perioperative dynamic change of T cell absolute count (A and D), B cell absolute count (B and E) and NK cell count (C and F) in gastric cancer patients according to postoperative hospital stay and complication. *Represents significant differences.
Figure 5Postoperative complication rate and median duration of hospital stay according to preoperative absolute count status of peripheral lymphocyte subsets (one decreased indicated one of T cell, B cell, or NK cell count was decreased; two decreased indicated two of T cell, B cell, or NK cell counts were decreased; three decreased indicated T cell, B cell, and NK cell counts were decreased).
The Comparison Between Patients with Prolonged Hospital Stay and Control Group (n=137)
| Variables | Prolonged Hospital Stay (n=22) | Normal Group (n=115) | |
|---|---|---|---|
| Age, mean (SD), years | 62.4±12.8 | 57.9±11.1 | |
| Gender | 0.176 | ||
| Male | 50.0% (11/22) | 65.2% (75/115) | |
| Female | 50.0% (11/22) | 34.8% (40/115) | |
| Body mass index mean (SD), kg/m2 | 23.5±4.1 | 22.7±3.3 | 0.347 |
| Smoking | 0.845 | ||
| No | 77.3% (17/22) | 79.1% (91/115) | |
| Yes | 18.2% (5/22) | 20.9% (24/115) | |
| Alcohol | |||
| No | 81.8% (18/22) | 81.7% (94/115) | 0.993 |
| Yes | 18.2% (4/22) | 18.3% (21/115) | |
| Hypertension | |||
| No | 68.2% (15/22) | 81.7% (94/115) | 0.149 |
| Yes | 31.8% (7/22) | 18.3% (21/115) | |
| Diabetes | |||
| No | 100% (22/22) | 95.7% (110/115) | 0.319 |
| Yes | 0% (0/22) | 4.3% (5/115) | |
| Albumin (g/L), mean (SD) | 38.5±4.8 | 40.1±4.3 | 0.113 |
| Prealbumin (mg/L), mean (SD) | 197.1±66.3 | 213.8±63.3 | 0.263 |
| Absolute lymphocyte count (*109/L), mean (SD) | 1.32±0.50 | 1.66±0.67 | 0.026 |
| Hemoglobin (g/L), mean (SD) | 114.1±24.0 | 117.4±26.0 | 0.578 |
| TNM stage | 0.426 | ||
| I/II | 68.2% (15/22) | 59.1% (68/115) | |
| III/IV | 31.8% (7/22) | 40.9% (47/115) | |
| Peripheral T cell count (/µL), mean (SD) | 841.5±372.3 | 1036.2±401.1 | |
| Peripheral B cell count (/µL), mean (SD) | 103.6±58.4 | 191.7±117.7 | |
| Peripheral NK cell count (/µL), mean (SD) | 168.9±73.3 | 265.1±96.8 | |
| NLR, median (IQR) | 2.0 (1.6, 3.0) | 3.2 (1.6, 4.3) | |
| LMR, median (IQR) | 3.6 (2.4, 4.9) | 3.3 (2.0, 4.6) | 0.612 |
| PLR, median (IQR) | 152.9 (117.1, 207.6) | 168.4 (93.6, 300.7) | 0.177 |
| Lymphocyte to CRP ratio | 0.82 (0.23, 2.78) | 1.89 (0.4, 4.38) | 0.504 |
| CRP to albumin ratio | 0.05 (0.01, 0.18) | 0.02 (0.01, 0.10) | 0.212 |
| Complications | |||
| No | 31.8% (7/22) | 94.8% (109/115) | |
| Grade 1 and 2 | 63.6% (14/22) | 5.2% (6/115) | |
| Grade 3 | 4.6% (1/22) | 0% (0/115) |
Notes: *Indicates significant difference.
Abbreviations: SD, standard deviation; TNM, tumor node metastasis; NK, natural killer; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein; IQR, interquartile range.
Univariate and Multivariate Logistic Regression Analyses of Factors Associated with Prolonged Hospital Stay and Complications After Operation (n=137)
| Hospital Stay | Complication | |||
|---|---|---|---|---|
| Variable | Univariate HR (95%CI) | Multivariate HR (95%CI) | Univariate HR (95%CI) | Multivariate HR (95%CI) |
| Age | ||||
| <60 years | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| ≥60 years | 3.47 (1.27–9.50) | 4.34 (1.04–18.20) | 2.46 (0.93–6.55) | 4.24 (1.26–14.3) |
| Gender | ||||
| Male | 1 (Ref) | N/A | 1 (Ref) | N/A |
| Female | 1.88 (0.75–4.70) 0.18 | 1.32 (0.51–3.40) 0.56 | ||
| Body mass index | 1.06 (0.93–1.22) 0.35 | N/A | 0.95 (0.83–1.10) 0.51 | N/A |
| Smoking | ||||
| No | 1 (Ref) | N/A | 1 (Ref) | N/A |
| Yes | 1.12 (0.37–3.33) 0.85 | 1.62 (0.57–4.63) 0.37 | ||
| Alcohol | ||||
| No | 1 (Ref) | N/A | 1 (Ref) | N/A |
| Yes | 1.00 (0.31–3.24) 1.00 | 1.50 (0.49–4.57) 0.48 | ||
| Albumin | 0.92 (0.83–1.02) 0.11 | N/A | 0.92 (0.83–1.02) 0.12 | N/A |
| Prealbumin | ||||
| ≥190 mg/L | 1 (Ref) | NS | 1 (Ref) | NS |
| <190 mg/L | 2.51 (0.99–6.37) | 2.26 (0.88–5.81) | ||
| Peripheral lymphocyte count | 0.35 (0.14–0.89) | NS | 0.69 (0.31–1.52) 0.35 | N/A |
| Hemoglobin | 1.00 (0.98–1.01) 0.58 | N/A | 0.99 (0.97–1.00) | N/A |
| NLR | ||||
| <2.8 | 1 (Ref) | NS | 1 (Ref) | NS |
| ≥2.8 | 4.28 (1.66–11.06) | 3.02 (1.17–7.80) | ||
| LMR | 0.92 (0.68–1.25) 0.61 | N/A | 1.12 (0.83–1.51) 0.46 | N/A |
| PLR | 1.00 (1.00–1.01) 0.18 | N/A | 1.00 (1.00–1.01) 0.55 | N/A |
| Lymphocyte to CRP ratio | 1.04 (0.92–1.18) 0.50 | N/A | 1.13 (1.01–1.27) | 1.24 (1.08–1.43) |
| CRP to albumin ratio | 1.75 (0.70–4.40) 0.24 | N/A | 1.26 (0.46–3.45) 0.66 | N/A |
| TNM stage | ||||
| II | 1 (Ref) | N/A | 1 (Ref) | N/A |
| III | 0.68 (0.26–1.78) 0.43 | 1.49 (0.58–3.79) 0.41 | ||
| Operation time | ||||
| ≤240 min | 1 (Ref) | NS | 1 (Ref) | 1 (Ref) |
| >240 min | 2.60 (0.99–6.84) | 3.08 (1.12–8.49) | 3.23 (1.0–10.5) | |
| Peripheral T cell count | ||||
| >720/µL | 1 (Ref) | NS | 1 (Ref) | NS |
| ≤720/µL | 3.37 (1.28–8.87) | 3.75 (1.40–10.1) | ||
| Peripheral B cell count | ||||
| >90/µL | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) |
| ≤90/µL | 7.19 (2.61–19.8) <0.01* | 3.61 (1.01–13.08) | 4.67 (1.68–12.9) | 7.05 (2.05–24.2) |
| Peripheral NK cell count | ||||
| >160/µL | 1 (Ref) | 1 (Ref) | 1 (Ref) | NS |
| ≤160/µL | 4.56 (1.64–12.7) | 4.28 (1.0–18.41) | 2.48 (0.94–6.54) | |
| Complication | ||||
| No | 1 (Ref) | 1 (Ref) | N/A | N/A |
| Grade 1–3 | 38.9 (11.5–131.4) <0.01* | 29.0 (7.06–119.1) | ||
Notes: *Indicates significant difference.
Abbreviations: HR, hazard ratio; TNM, tumor node metastasis; NK, natural killer; N/A, not applicable; NS, no significant difference; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLR, platelet to lymphocyte ratio; CRP, C-reactive protein; IQR, interquartile range.